

## MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

## Licensee

1. Covenant Medical Center, Inc.
2. 1447 N. Harrison  
Saginaw, MI 48602

In accordance with letter dated

April 23, 2012,

3. License number 21-01492-02 is amended in its entirety to read as follows:

4. Expiration date December 31, 2014

5. Docket No. 030-02012  
Reference No.

- |   |   |  |
|---|---|--|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form  | 8. Maximum amount that licensee may possess at any one time under this license |
| A. Any byproduct material permitted by 10 CFR 35.100  | A. Any  | A. As needed   |
| B. Any byproduct material permitted by 10 CFR 35.200  | B. Any  | B. As needed   |
| C. Any byproduct material permitted by 10 CFR 35.300  | C. Any  | C. As needed (not to exceed 1 curie of iodine-131)                             |
| D. Any byproduct material permitted by 10 CFR 35.400  | D. Sealed Sources (Implant Sciences Model No. 3500; Medi-Physics, Inc., d/b/a GE Healthcare, Model No. 6711 (OncoSeed™); Mentor Model No. I-125SL or I-125SH; and IsoAid L.L.C. Model IAI-125A)   | D. 1.15 curies   |
| E. Any byproduct material permitted by 10 CFR 31.11   | E. Prepackaged Kits   | E. 5 millicuries   |
| F. Iodine-125 as permitted by 10 CFR 35.1000          | F. Sealed Sources (Bard Brachytherapy, Inc., Model No. STM 1251; IsoAid L.L.C., Model No. IAI-125A (Advantage™ I-125); Medi-Physics, Inc., d/b/a GE Healthcare, Model No. 6711 (OncoSeed™); and Core Oncology, Inc. (formerly Mills Biopharmaceuticals, LLC), Model No. I-125 SL (ProstaSeed™)) | F. 15 millicuries  |

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number

21-01492-02

Docket or Reference Number

030-02012

**Amendment No. 60**

## 9. Authorized use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
- D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
- E. In vitro studies.
- F. **For use as temporary implants to localize non-palpable lesions. Limited to 1.5 millicuries per treatment.**

CONDITIONS

- 10.
  - A. Licensed material in **Subitem Nos. 6.A. through 6.F.**, excluding iodine-131 for thyroid carcinoma therapies, may be used at the licensee's facilities located at 5400 Mackinaw Road, Saginaw, Michigan.
  - B. Licensed material in **Subitem Nos. 6.A., 6.B., 6.C., and 6.E.** may be used at the licensee's facilities located at 700 Cooper Avenue, Saginaw, Michigan.
  - C. Licensed material in **Subitem Nos. 6.A. and 6.B.** may be used at the licensee's facilities located at 318 W. Wright Avenue, Shepherd, Michigan.
  - D. Licensed materials listed in Subitem No. 6.B. may be used at the licensee's facilities located at 4884 Berl Drive, Saginaw, Michigan.
  - E. **Licensed material in Subitem No. 6.F. may be used at the licensee's facilities located at the Harrison Campus, 1447 North Harrison, Saginaw, Michigan, and at the Houghton Campus, 1000 Houghton, Saginaw, Michigan.**
- 11. The Radiation Safety Officer for this license is Mark Robert Ludka, M.D.
- 12. Licensed material is only authorized for use by, or under the supervision of:
  - A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
  - B. The following individuals are authorized users for medical use as indicated:

Authorized Users

Joseph E. Talbot, M.D.

Scott E. Cheney, M.D.

Material and Use

10 CFR 35.100, 35.200, and 35.300.

10 CFR 35.100 and 35.200.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License Number  
21-01492-02Docket or Reference Number  
030-02012**Amendment No. 60**Authorized UsersMaterial and Use

Sanjay J. Talati, M.D.	10 CFR 35.100 and 35.200.
George F. Ascherl, M.D.	10 CFR 35.100, 35.200, and 35.300.
Harvey Yee, M.D.	10 CFR 35.100, 35.200, and 35.300.
C.E. Mueller, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.
Robert B. Saltzman, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.
Mark Robert Ludka, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.
Kristin M. Nelsen, M.D.	10 CFR 35.100, 35.200, and 31.11.
Rajnikant H. Mehta, M.D.	10 CFR 35.400.
Rajesh P. Kotecha, M.D.	10 CFR 35.400.
Paul G. Kocheril, M.D.	10 CFR 35.400 and 35.1000 (limited to iodine-125 for temporary implants to localize non-palpable lesions).
James F. Littles, M.D.	10 CFR 35.400.
Sigrid E. Messana, D.O.	10 CFR 35.100, 35.200, and 31.11.
Chirdeep Bhutani, M.D.	10 CFR 35.100, 35.200, and 35.300.
Sambasiva Kottamasu, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.
Ramesh Vedula, M.D.	10 CFR 35.400.
Sultan Bhimani, M.D.	10 CFR 35.100, 35.200, and 31.11.
Ram K. Gadani, M.D.	10 CFR 35.100, 35.200, 35.300, and 35.400.
Steve Min, D.O.	10 CFR 35.100, 35.200, and 35.300.
K. K. Ravindran, M.D.	10 CFR 35.200.
Umesh Badami, M.D.	10 CFR 35.200.

13. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License Number  
**21-01492-02**Docket or Reference Number  
**030-02012****Amendment No. 60**

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.


A. Application dated September 24, 2004; and

B. Letters dated August 21, 2006, December 4, 2006, July 31, 2009, July 13, 2010, **April 23, 2012**, and **July 10, 2012**.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date JUL 16 2012

By



Toye L. Simmons  
Materials Licensing Branch  
Region III